Skip to main content
. Author manuscript; available in PMC: 2012 Dec 9.
Published in final edited form as: Lancet Oncol. 2010 Apr 29;11(6):561–570. doi: 10.1016/S1470-2045(10)70071-1

Table 3.

Anti-tumour efficacy in the extremity subgroup (N=149; all patients randomly allocated treatment)

EIA plus RHT (N=76) EIA (N=73) Hazard ratio (95% CI) p value*
Local progression-free survival
Exremity (months) Not reached Not reached 0.63 (0.32–1.28) 0.20
Proportion (%) at 2 years 92 (85–98) 80 (71–89) .. ..
Proportion (%) at 4 years 82 (73–93) 76 (66–87) .. ..
Disease-free survival
Median duration (months) 43 (30 to >120) 43 (19 to >120) 0.79 (0.51–1.23) 0.29
Proportion (%) at 2 years 70 (60–81) 57 (47–69) .. ..
Proportion (%) at 4 years 49 (38–63) 49 (39–62) .. ..
Overall survival
Number of deaths 24 26 0.93 (0.53–1.62) 0.80
Median duration (months) Not reached Not reached .. ..
Proportion (%) at 2 years 89 (82–96) 81 (72–90) .. ..
Proportion (%) at 4 years 67 (56–80) 69 (59–81) .. ..

EIA=etoposide+ifosfamide+doxorubicin. RHT=regional hyperthermia.

*

Calculated by log-rank test.